The Korean Journal of Medicine

  • 제93권4호
  • /
  • Pages.344-350
  • /
  • 2018
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

통풍의 새로운 진단 분류 기준과 치료 지침

New Classification Criteria and Guideline for Management of Gout

  • 송정수 (중앙대학교 의과대학 내과학교실 류마티스내과)
  • Song, Jung Soo (Division of Rheumatology, Department of Internal Medicine, Chung-Ang University School of Medicine)
  • 발행 : 2018.08.01
⟨ 이전 논문 다음 논문 ⟩

초록

Gout is a chronic systemic metabolic disease characterized by recurrent attacks of inflammatory arthritis resulting from the precipitation of monosodium urate crystals, which has various clinical and pathological manifestations. The disease is associated with multiple comorbidities, an impaired quality of life, and a heavy economic burden. The incidence and prevalence of gout is increasing in many developed and developing countries, as in Korea. Gout is diagnosed by confirming monosodium urate crystals in the synovial fluid or affected tissue. If crystal documentation is unavailable, new gout classification criteria presented by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2015 can be applied. There are many guidelines for managing gout published in the United States, Japan, and Europe. However, there are no guidelines for the tailored management of gout for Korean patients. This review describes a new classification for the diagnosis of gout and management guidelines.

키워드

참고문헌

  1. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007;46:1441-1444. https://doi.org/10.1093/rheumatology/kem150
  2. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310-1316.
  3. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009;48:582-586.
  4. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Rheum 2007;57:109-115. https://doi.org/10.1002/art.22466
  5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900. https://doi.org/10.1161/CIRCULATIONAHA.107.703389
  6. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;20:1029-1033. https://doi.org/10.3346/jkms.2005.20.6.1029
  7. Jung JH, Song GG, Ji JD, et al. Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med 2018 ;33:815-822. https://doi.org/10.3904/kjim.2016.062
  8. Kuo CF, Yu KH, See LC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine 2011;78:577-580. https://doi.org/10.1016/j.jbspin.2011.01.007
  9. Son KM, Seo YI, Kim IJ, et al. Adherence to uric acid lowering agent of gouty patients. J Korean Rheum Assoc 2010;17:162-167. https://doi.org/10.4078/jkra.2010.17.2.162
  10. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American college of rheumatology/ European league against rheumatism collaborative initiative. Arthritis Rheumatol 2015;67:2557-2568. https://doi.org/10.1002/art.39254
  11. Lee CH, Sung NY. The prevalence and features of Korean gout patients using the national health insurance corporation database. J Rheum Dis 2011;18:94-100. https://doi.org/10.4078/jrd.2011.18.2.94
  12. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-1446. https://doi.org/10.1002/acr.21772
  13. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447-1461.
  14. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011;30:1018-1029. https://doi.org/10.1080/15257770.2011.596496
  15. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-1311. https://doi.org/10.1136/ard.2006.055251
  16. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324. https://doi.org/10.1136/ard.2006.055269
  17. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900. https://doi.org/10.1002/art.1780200320
  18. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010;170:1120-1126.
  19. Pelaez-Ballestas I, Hernandez Cuevas C, Burgos-Vargas R, et al. Diagnosis of chronic gout: evaluating the American College of Rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. J Rheumatol 2010;37:1743-1748. https://doi.org/10.3899/jrheum.091385
  20. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009;15:22-24. https://doi.org/10.1097/RHU.0b013e3181945b79
  21. Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology 2011;261:516-524. https://doi.org/10.1148/radiol.11102485
  22. Naredo E, Uson J, Jimenez-Palop M, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 2014;73:1522-1528.
  23. Louthrenoo W, Jatuworapruk K, Lhakum P, Pattamapaspong N. Performance of the 2015 American College of Rheumatology/European league against rheumatism gout classification criteria in Thai patients. Rheumatol Int 2017;37:705-711. https://doi.org/10.1007/s00296-017-3708-3
  24. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200-1210. https://doi.org/10.1056/NEJMoa1710895
  25. Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: a population-based cohort study. Circulation 2018 Jul 24 [Epub]. https://dx.doi.org/10.1161/CIRCULATIONAHA.118.033992.

피인용 문헌

  1. A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum vol.12, pp.12, 2018, https://doi.org/10.3390/nu12123794
  2. 통풍의 한의임상진료현황 - 온라인(웹기반) 설문조사 vol.38, pp.1, 2018, https://doi.org/10.14406/acu.2021.003